Replies to post #77647 on Avid Bioservices Inc (CDMO)

[freethemice]

Thanks Entdoc, Yes, that has always been the problem, that you have to first try the treatment in the
sickest of patients, i.e. those that have nothing to lose by trying an experimental therapy. Only if that
works can you try it earlier. Also, the time involved is shortest for those advanced cases, and investors
are impatient, and time is money, sorry to say.
I totally agree that the best use of the treatment may not be discovered until it has been used for a while.
I think that applies to many areas of science. As for bavituximab, I think it is on the right track,
although I think it will need some help. Hopefully, it can be approved for something so that more money for
research on new uses can be available. Like you, I think it needs to be coupled to something else to give
it enough power to help in the more advanced cases. I like the immunocytokine approach, probably
using IL-12. But first we need to get it approved with chemo, and then try the immunocytokine with chemo
in human patients.

[geocappy1]

I do like the idea that eventually we will find an application for Bavi, however, as for making money on the investment, IMO sooner rather than later is necessary and desirable. The way our management team raises money and spends, the "eventually" will mean little return for the long-term shareholders.

The other undeniable reality for those who have been in experimental medicine is this: If an agent is bioactive, anti-inflammatory or ant-neoplastic AND proven safe, it will probably have an application. Keep using it in the clinic long enough and another possibly more important secondary indication for its use will be found

[freethemice]

This article is open access and so available to anyone.
http://www.pnas.org/content/early/2012/03/20/1121629109.abstract
PDF and quicktime movies (supporting info)